

Meet the Praxis SCI Accelerate 2022 Cohort

Praxis Spinal Cord Institute is pleased to announce the cohort of four high-impact technology ventures.

Carefully selected by a panel of spinal cord injury (SCI) consumers, researchers, and commercial leaders, these four companies address key challenges for people with SCI and have potential to transform healthcare outcomes for the broader community.

Praxis Spinal Cord Institute's SCI Accelerate program is made possible through support from:





Western Economic Diversification Canad Diversification de l'économie de l'Ouest Canada







Our Cohort

Comphya

Novel therapy to restore erectile function

Game Changer





Meet the 2022 Cohort



"A technology based on neuroprosthetics principles and consists of implanting electrodes in the pelvic cavity"

comphya.com

Comphya is a Swiss medical device company developing the first implantable neurostimulator to treat erectile dysfunction in non-responders to oral drugs, such as spinal cord injury individuals. Their technology is based on neuroprosthetics principles and consists of implanting electrodes in the pelvic cavity. The device named CaverSTIM will provide self-controlled stimulation (via a wireless remote control) to the distal portion of the disrupted cavernous nerve. This envisioned medical device will improve the actual methods for the treatment of erectile dysfunction in spinal cord injury individuals, providing a safer, non-traumatic, comfortable, spontaneous and more effective alternative.

Game Changer

"Developing a new class of wheeled mobility technology" gamechangertech.ca

Game Changer Technologies Inc. is a British Columbia-based technology company, focusing on bringing solutions to improve the quality of life for those living with spinal cord injury/mobility issues. With our patent pending technology, Game Changer is developing a new class of wheeled mobility technology.



"Intelligent wearables to revolutionize physical therapy" inteligex.ca

Inteligex is a Canadian biotechnology company developing therapies to reduce the personal, societal and financial costs incurred by spinal cord injuries and other diseases of the central nervous system. Inteligex has developed two proprietary bioengineered neural stem cell-based products (one targeting the acute stage of injury and one focusing on the chronic stage). Inteligex's cells are specifically designed to integrate into the injury microenvironment. They are now working to translate these human stem cell technologies for use in the clinic.



"The first wheelchair control system based on smart glasses called munevo DRIVE" munevo.com

Munevo GmbH / **Munevo Inc.** is an early stage medical device company that focuses on assistive technology based on smart glasses. Munevo developed the first wheelchair control system based on smart glasses called munevo DRIVE. Through simple and adaptive head motions people can control their wheelchair hands-free while being able to connect to their environment. The solution has been approved as a medical device in the EU in 2019 and has now started commercialization in North America.

Interested in investing, mentoring or collaborating with these companies? Get in touch with us:

Arushi Raina

T: 604.827.0720

E: araina@praxisinstitute.org